Compare Deere & Company (DE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs TG Therapeutics Inc — how do they compare? Deere & Company trades at $620.38 (market cap $166.81B), while TG Therapeutics Inc trades at $49.66 (market cap $7.64B). The key difference: Deere & Company is far larger — about 21.8× TG Therapeutics Inc's market cap, and Deere & Company pays a 1.05% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DE | TGTX | |
|---|---|---|
Market Cap | $166.81B | $7.64B |
Sector | Industrials | Health |
52-Week High | $662.49 | $59.06 |
52-Week Low | $439.11 | $26.94 |
Enterprise Value | $221.63B | $7.84B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $619.82, up 1.73% in the last session, reflecting positive momentum amid a bullish technical signal. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $6.55 surpassing the $5.70 forecast. However, revenue declined to $44.67 billion in 2025, and net income margin compressed to 10.33%. The stock's valuation multiples, including a P/E of 35.01, are elevated relative to historical norms, while analyst consensus leans moderate buy with a $669.79 price target.
The outlook for DE hinges on agricultural demand recovery, but near-term risks include weak North American equipment sales and margin pressure. Upside potential exists if earnings sustain beats and cost controls improve profitability, yet investors face cyclical industry exposure and high debt levels. The current price near resistance at $620 suggests cautious entry points may be prudent pending Q2 2026 results.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
